J
The FDA issued its first approval of a CRISPR gene-editing therapy.
The US Food and Drug Administration announced the approval of two gene-based therapies for sickle cell disease, one of which uses the genome editing technology CRISPR. It’s a big milestone, but access to the therapies for now will still be very limited and expensive, the New York Times explains.
Follow topics and authors from this story to see more like this in your personalized homepage feed and to receive email updates.
Loading comments
Getting the conversation ready...
